AnaptysBio - Home
About
Overview
Strategy
Management
Board of Directors
Research and Development Committee
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Imsidolimab
ANB030
ANB032
Partnerships
Investors / News
Overview
News
Events
Goverance
Stock Information
Analyst Coverage
SEC Filings
FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Toggle
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
October 26, 2020
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
October 13, 2020
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
About
Technology
Pipeline
Investors
Careers
